All In Biotech

Drug Trial Radar · NCT06675175

A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease

Last checked: Nov 19, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Dec 9, 2024

Primary completion

Oct 27, 2025

Study completion Oct 27, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability and the pharmacodynamics (PD) of AZD4144 following oral administration in participants with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD).

Conditions

  • Chronic Kidney Disease
  • Atherosclerotic Cardiovascular Disease

Interventions

  • AZD4144Drug

    Oral solution of AZD4144 will be given to randomised participants as per the arm they have been assigned.

  • PlaceboOther

    Placebo will be given orally to randomized participants as per the arm they are assigned.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse eventsTime frame: From first dose (Day 1) until Follow-up (Day 56±1)
  2. Relative change from baseline to 4 weeks in systemic Interleukin-6 (IL-6) levelsTime frame: Day 1 to Day 28

Locations

15 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    Glendale, California

  • Research Site

    Daytona Beach, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Port Orange, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Farmington Hills, Michigan

  • Research Site

    The Bronx, New York

  • Research Site

    Sherman, Texas

  • Research Site

    Pleven, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Gyöngyös, Hungary

  • Research Site

    Kistarcsa, Hungary

  • Research Site

    Bucharest, Romania

  • Research Site

    Cluj-Napoca, Romania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.